Mantaro Precious Metals Corp Ordinary Shares Azioni (OTC: MSLVD)

Ultime notizie per Mantaro Precious Metals Corp Ordinary Shares (OTC:MSLVD) Azioni

Mantaro Precious Metals Corp Ordinary Shares

NV5 Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.41 by 7.32 percent. This is a 22.22 percent increase over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $250.885 million which missed the analyst consensus estimate of $252.108 million by 0.49 percent. This is a 4.85 percent increase over sales of $239.287 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

NVEE

NV5 Global Q3 2024 Adj. EPS $0.44 Beats $0.41 Estimate, Sales $250.885M Miss $252.108M Estimate

FRLA

Fortune Rise Acquisition Extends To Complete Business Combination From Nov. 5 To Dec. 5

WIIM

PRPH

ProPhase Labs shares are trading lower after the company announced its intention to sell shares through a public offering.

Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.02 by 200 percent. The company reported quarterly sales of $213.300 million which beat the analyst consensus estimate of $210.729 million by 1.22 percent. This is a 11.15 percent increase over sales of $191.900 million the same period last year.

MYGN

Myriad Genetics Q3 2024 Adj. EPS $0.06 Beats $0.02 Estimate, Sales $213.300M Beat $210.729M Estimate

Buybacks

DVAX

Dynavax Launches $200M Share Buyback Program With Board Approval; Repurchases Expected To Be Completed Within One Year

ON24 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTF#NYSE">ONTF</a>) raises FY2024 Adj EPS guidance from $0.05-0.08 to $0.08-0.10 vs $0.07 analyst estimate. Raises FY2024 sales outlook from $145.00 million-147.80 million to $146.80 million-147.80 million vs $146.33 million estimate.

Guidance

ONTF

ON24 Raises FY2024 Adj EPS Guidance from $0.05-0.08 to $0.08-0.10 vs $0.07 Est; Raises FY2024 Sales Guidance from $145.00M-147.80M to $146.80M-147.80M vs $146.33M Est

Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) affirms FY2024 sales outlook from $1.40 billion-1.60 billion to $1.40 billion-1.60 billion.

Bloom Energy Affirms FY2024 Sales Guidance to $1.40B-1.60B  VS Est.1.47B

Phunware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 90 percent increase over losses of $(2.50) per share from the same period last year. The company reported quarterly sales of $665.00 thousand which missed the analyst consensus estimate of $1.31 million by 49.24 percent. This is a 46.88 percent decrease over sales of $1.25 million the same period last year.

PHUN

Phunware Q3 EPS $(0.25) Beats $(0.26) Estimate, Sales $665.00K Miss $1.31M Estimate

Apartment Inv &amp; Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIV#NYSE">AIV</a>) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 700 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $53.16 million which beat the analyst consensus estimate of $52.60 million by 1.06 percent. This is a 11.44 percent increase over sales of $47.70 million the same period last year.

Apartment Inv & Mgmt Q3 EPS $(0.16) Misses $(0.11) Estimate, Sales $53.16M Beat $52.60M Estimate

New facility will enable testing of liquid hydrogen (LH2), liquid oxygen (LOX) and liquid methane (LCH4)

Graham To Construct Cryogenic Propellant Testing Facility

ON24 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTF#NYSE">ONTF</a>) is looking for Q4 Adj EPS of $0.01-0.02 vs $0.01 analyst estimate. sees sales of $35.400 million-36.400 million vs $35.87 million estimate.

ON24 Sees Q4 Adj EPS $0.01-0.02 vs $0.01 Est; Sees Sales $35.400M-36.400M vs $35.87M Est

MRVI

Maravai LifeSciences To Acquire Officinae Bio's DNA And RNA Business, Enhancing Nucleic Acid Research Capabilities; Acquisition To Boost Maravai's mRNA Manufacturing Through TriLink BioTechnologies

Lionsgate Studios (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LION#NASDAQ">LION</a>) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.06) by 550 percent. This is a 750 percent decrease over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $823.70 million which beat the analyst consensus estimate of $748.00 million by 10.12 percent.

LION

Lionsgate Studios Q2 2025 GAAP EPS $(0.39) Misses $(0.06) Estimate, Sales $823.70M Beat $748.00M Estimate

Lantronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRX#NASDAQ">LTRX</a>) is looking for Q2 Adj EPS of $0.01-0.05 vs $0.10 analyst estimate. sees sales of $29.000 million-33.000 million vs $38.60 million estimate.

LTRX

Lantronix Sees Q2 Adj EPS $0.01-0.05 vs $0.10 Est; Sees Sales $29.000M-33.000M vs $38.60M Est

FIGS

FIGS shares are trading lower after the company reported worse-than-expected Q3 revenue results and cut its FY24 revenue guidance.

BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) is looking for Q4 Adj EPS of $0.47-0.52 vs $0.51 analyst estimate. seessales of $167.000 million-169.000 million vs $168.08 million estimate.

BlackLine Sees Q4 Adj EPS $0.47-0.52 vs $0.51 Est; Sees Sales $167.000M-169.000M vs $168.08M Est

Adeia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADEA#NASDAQ">ADEA</a>) lowers FY2024 sales outlook from $380.00 million-420.00 million to $370.00 million-400.00 million.

ADEA

Adeia Lowers FY2024 Sales Guidance from $380.00M-420.00M to $370.00M-400.00M

Longboard Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBPH#NASDAQ">LBPH</a>) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.57) by 10.53 percent.

LBPH

Longboard Pharmaceuticals Q3 2024 GAAP EPS $(0.63) Misses $(0.57) Estimate

BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) raises FY2024 Adj EPS guidance from $2.08-2.21 to $2.15-2.21 vs $2.14 analyst estimate. Raises FY2024 sales outlook from $647.00 million-651.00 million to $651.00 million-653.00 million vs $649.14 million estimate.

BlackLine Raises FY2024 Adj EPS Guidance from $2.08-2.21 to $2.15-2.21 vs $2.14 Est; Raises FY2024 Sales Guidance from $647.00M-651.00M to $651.00M-653.00M vs $649.14M Est

Information Servs Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/III#NASDAQ">III</a>) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.06 by 16.67 percent. This is a 54.55 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $61.28 million which beat the analyst consensus estimate of $60.50 million by 1.28 percent. This is a 14.62 percent decrease over sales of $71.77 million the same period last year.

Comments

Mantaro Precious Metals Corp Ordinary Shares

Notizie

Ultime notizie per Mantaro Precious Metals Corp Ordinary Shares (OTC:MSLVD) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO